Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody.

G Morstyn; S M Hsu; T Kinsella; H Gratzner; A Russo; J B Mitchell

doi:10.1172/JCI111145

Using a monoclonal antibody to bromodeoxyuridine (BUdR) and immunohistochemistry, we measured the incorporation of this thymidine analogue into the DNA of human normal and malignant cells exposed in vivo. BUdR given as a constant intravenous infusion for 12 or 24 h daily for up to 13 d resulted in a steady-state plasma level of 10(-6) M during the infusion. We demonstrated extensive incorporation of BUdR into both normal skin, normal bone marrow, and malignant melanoma cells. In addition, this infusion of BUdR was adequate to identify sister chromatid exchanges from human marrow chromosomes exposed in vivo. Using this constant infusion, significant but reversible (acute) toxicity was observed with myelosuppression and skin photosensitivity. These techniques, which are considerably less cumbersome and time-consuming than the use of radioactive isotopes of thymidine, can be used for further human studies of cell kinetics and chromosomal replication in both normal and malignant cells.

Images.

Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody.

G Morstyn, S M Hsu, T Kinsella, H Gratzner, A Russo, and J B Mitchell

Article tools

Metrics

Go to

Bromodeoxyuridine in tumors and chromosomes detected with a monoclonal antibody.

G Morstyn, S M Hsu, T Kinsella, H Gratzner, A Russo, and J B Mitchell

Article tools

Metrics

Go to

Sign up for email alerts